 NEW YORK--BUSINESS WIRE--Odonate Therapeutics, Inc. NASDAQ: ODT, a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2020. As of December 31, 2020, Odonate had 157.3 million in cash, compared to 180.5 million as of December 31, 2019. This decrease in cash resulted primarily from cash used in operating activities for 